AI assistant
Centessa Pharmaceuticals plc — Director's Dealing 2021
May 28, 2021
31309_dirs_2021-05-27_6e9f047e-907a-4c0d-b3f3-869d9c820cfd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Centessa Pharmaceuticals plc (CNTA)
CIK: 0001847903
Period of Report: 2021-05-27
Reporting Person: Thorell Marella (Chief Accounting Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Share Option (right to buy) | $4.11 | 2030-09-30 | Ordinary Shares (58956) | Direct | |
| Share Option (right to buy) | $4.87 | 2030-12-30 | Ordinary Shares (9487) | Direct | |
| Share Option (right to buy) | $5.84 | 2031-02-19 | Ordinary Shares (208474) | Direct |
Footnotes
F1: 56.25% of the shares subject to such option are vested as of January 29, 2021. The remaining 43.75% of the shares subject to such option shall vest and become exercisable monthly beginning on February 1, 2021.
F2: Represents A Ordinary Shares that will be redesignated as Ordinary Shares immediately prior to the closing of the initial public offering.
F3: Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F4: 25% of the shares subject to such option are vested as of January 29, 2021. The remaining 75% of the shares subject to such option shall vest and become exercisable monthly beginning on February 1, 2021.
F5: 25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.